日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Application given for gene therapy trials to treat blood disease

By Liu Zhihua | chinadaily.com.cn | Updated: 2021-01-19 14:44
Share
Share - WeChat
A screenshot from EdiGene's official website. [Photo/edigene.com]

Chinese biotech company EdiGene Inc announced on Monday the Center for Drug Evaluation of the China National Medical Products Administration has approved the company's Investigational New Drug application for ET-01, a CRISPR/Cas 9 gene-editing therapy for patients with transfusion dependent β-thalassemia, a blood disease characterized by severe anemia and a lifelong dependence on red blood cell transfusions that can lead to iron overload.

That marks the first gene-editing therapy and the first hematopoietic stem cell therapy IND application approval in China.

The Beijing-based company develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases. Previously, the company announced the acceptance of the IND by CDE on Oct 27, 2020.

Wei Dong, CEO of EdiGene, said the company will roll out phase I clinical trials soon.

"We are embarking on a new journey as a clinical-stage company. We will continue to translate cutting-edge gene-editing technology and advance our pipeline, with a goal of providing better choices for patients in China and around the world," he said.

ET-01 is an investigational, autologous, ex vivo gene-editing therapy. The approved trial of ET-01 is a multicenter, open-label, single arm study designed to assess safety and efficacy in transfusion dependent β-thalassemia patients.

In China, it is estimated there are over 300,000 patients with thalassemia major or thalassemia intermediate. Serious unmet medical needs remain for transfusion dependent β-thalassemia patients today.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 大片免费看费看大片 | 国产精品无码永久免费888 | 国产在线伊人 | 亚洲精品综合久久 | 精品一区二区三区四区五区六区 | 99久久久国产精品 | 免费黄色片网站 | 欧美一区二区三区四区视频 | 国产精品视频网 | 亚洲精品一区二区三区在线看 | 欧美成人免费全网站大片 | 国产美女亚洲精品久久久综合 | 曰本一级毛片免费 | 日本三级免费 | 97色伦网| 国产精品成人品 | 日本中文字幕电影 | 婷婷狠狠干 | 中文字幕日韩一区二区 | 十八勿入 | 亚洲无线一二三四手机 | 日韩国产无矿砖一线二线图 | 天天摸夜夜摸夜夜狠狠摸 | 亚洲午夜成激人情在线影院 | 91手机在线观看 | 日本精品人妻无码免费大全 | 免费一级做a爰片性色毛片 狠狠色欧美亚洲狠狠色www | 国产成人综合在线观看 | 麻豆国产 | 天天做天天爱天天综合网 | 一区二区成人国产精品 | 亚洲欧美中文日韩在线v日本 | 欧美日韩一区二区三区自拍 | 国产欧美成人 | 久久免费视频一区二区三区 | 亚洲欧美日韩一区二区 | 色聚网久久综合 | 精品伊人 | 日韩电影免费在线观看中文字幕 | 国产精品无码永久免费888 | 欧美一区 |